bioAffinity Technologies Inc. (NASDAQ: BIAF) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT BIOAFFINITY TECHNOLOGIES INC.

bioAffinity Technologies Inc. (NASDAQ: BIAF)
Listen to this Section


$0.85
+0.0132 ( +1.59% ) 578.1K

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Market Data


Open $0.85
Previous Close $0.83
Volume 578.1K
Market Cap $3.95M
Day Range $0.81 - $0.87
52 Week Range $0.69 - $13.80
Shares Outstanding 4.74M
Change % +1.59%
Net Change ▲ 0.0132
Insider Ownership -0.01%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
IPO Year2022
CountryUnited States
UnderwriterWallachBeth Capital, Craft Capital Management, more

Insider Ownership Transactions

Total Amount Purchased: -874,267.00

Date Type Amount Purchased Purchaser
2024-07-02 Sale -33784.00 Anderson Robert A.
2024-07-02 Sale -33784.00 KNIGHT PETER S
2024-07-02 Sale -33784.00 GIRGENTI STEVEN
2024-07-02 Sale -33784.00 DIAMOND STUART
2024-07-02 Sale -33784.00 Rubin Gary D
2024-07-02 Sale -33784.00 Platt Jamie
2024-07-02 Sale -33784.00 Joyce Roby
2024-07-02 Sale -33784.00 Zannes Maria
2024-06-14 Sale -8296.00 Zannes Maria
2024-06-14 Sale -8296.00 GIRGENTI STEVEN

SEC Filings


Form Type Description Pages Date
8-k 8K-related 16 Sep 17, 2025
s-1/a Registration statements 16 Sep 15, 2025
8-k 8K-related 15 Sep 09, 2025
8-k 8K-related 32 Sep 05, 2025
8-k 8K-related 16 Sep 03, 2025
8-k 8K-related 15 Sep 02, 2025
s-1 Registration statements 16 Aug 29, 2025
8-k 8K-related 15 Aug 18, 2025
8-k 8K-related 16 Aug 14, 2025
10-q Quarterly Reports 80 Aug 14, 2025

Latest News


× Before browsing our site, please accept our cookies policy